

REMARKS

Reconsideration is requested.

Claims 1, 2 and 4-9 are pending.

The Section 112, first paragraph "written description", rejection of claims 1, 2 and 4-9 is traversed. Reconsideration and withdrawal of the rejection are requested in view of the following.

The Remarks of the Amendment filed March 17, 2009 stated that support for the amended claims could be found on pages 2-3 of the specification. The Examiner is understood to believe that the amended passages of the claims are allegedly not adequately described in the specification.

Claim 1 was revised, without prejudice, in the Amendment filed March 17, 2009, and above to further describe the previously recited inhibitor of synthesis of an extracellular matrix, of cell proliferation and migration, and of inflammation, as

a decorin peptide or biologically active fragment of decorin selected from the group consisting of (a) a decorin peptide comprising signal peptide and propeptide, (b) a 15-20 kDa biologically active fragment of decorin comprising amino acids 115 to 260 of decorin, (c) a biologically active fragment of decorin comprising a leucine-rich repeat, protein core (38-43 kDa) sequence of decorin and (d) a biologically active fragment of decorin comprising a decorin loop structure formed from cysteine residues

Page 2, lines 4-5 of the specification describes that novel compounds are used according to the invention to develop coatings for platforms according to the invention.

Page 2, lines 5-7 of the specification describes that the platforms may be prostheses and can include stents which have coatings.

Page 2, lines 8-10 of the specification describes that the invention involves use of multi-functional compounds to produce pharmacologically active coatings on a platform or prosthesis.

Page 2, lines 11-12 describes that the coatings of the invention make it possible to avert arterial restenosis in a situation of mechanical trauma of the tissues where an inflammatory response is created. Page 2, lines 13-18 also describe an advantage of the invention in that thrombosis can be averted.

Page 2, lines 19-22 of the specification describes that decorin and/or peptide fragments of decorin and related derivatives and fragments possessing the properties of these compounds are used according to the invention, as coatings for platforms according to the invention.

Page 2, lines 23-24 of the specification describes as how human decorin is a protein comprising 359 amino acids with a chain of glycosaminoglycans, with a molecular weight of 100-120 kDa.

Page 2, lines 24-31 of the specification describes the amino acid sequence of human decorin, which corresponds to SEQ ID NO: 1 of the Sequence Listing.

Page 2, line 32 through page 3, line 5 of the specification describes separate domains of decorin which are useful in the disclosed invention. Specifically, Domain I is the signal peptide and propeptide of decorin, Domain II is the cysteine residues and glycosaminoglycans (GAGs) attachment site of decorin, Domain III is the leucine-rich repeats (LRR), protein core (38-43 kDa), and Domain IV is the cysteine residues with loop.

Page 3, lines 6-8 of the specification describes further active decorin fragments as a decorin fragment which is between amino acid positions 115 and 260, and has a molecular weight of 15-20 kDa.

Page 3, lines 9-19 of the specification describes that the presence of these compounds of the invention when present on a platform of the invention allows exploitation of their multifunctional properties and makes it possible to act on cell proliferation (such as by inhibiting degradation of the extracellular matrix), cell migration (such as by inhibiting migration), and inflammation (such as by inhibiting the inflammatory action of interleukin 1 and the inflammatory response to angioplasty trauma on the smooth muscular cells by maintaining their contractile phenotype), in the manner described in the text.

Page 3, lines 28-30 of the specification describes platforms and prostheses of the invention which contain a therapeutically effective quantity of decorin and/or a peptide fragment of decorin, and/or a derivative of decorin or a fragment of decorin.

Claim 1 of the March 17, 2009 was revised, without prejudice, to specifically recited, for example, the embodiments of the active compounds of the invention described as Domain I ("(a) a decorin peptide comprising signal peptide and propeptide") described on page 3, line 1 of the specification, the active protein fragment described on page 3, lines 6-8 of the specification (i.e., "(b) a 15-20 kDa biologically active fragment of decorin comprising amino acids 115 to 260 of decorin"), Domain III (i.e., "(c) a biologically active fragment of decorin comprising a leucine-rich repeat sequence of decorin") described on page 3, line 4 of the specification, and Domain IV

(i.e., "(d) a biologically active fragment of decorin comprising a decorin loop structure formed from cysteine residues") described on page 3, line 5 of the specification.

The revisions of claim 1 in the Amendment filed March 6, 2009 were also included in claim 2. Additionally, claim 2 was revised, without prejudice, to include chemically modified derivatives of the inhibitors (a), (b), (c) and (d) of claim 2, as was originally described in the unamended claim 2 and, for example, on page 2, lines 19-22 of the specification.

The revisions of claim 1 in the Amendment filed March 6, 2009 were also included in claim 4 and 5.

New claim 7 of the Amendment filed March 6, 2009 finds support in the specification at, for example, page 2, lines 4-10 and page 3, lines 28-30.

New claim 8 of the Amendment filed March 6, 2009 finds support in the specification at, for example, page 4, lines 3-5 of the specification as the above-noted passages describing aspects of claims 1 and 2.

New claim 9 of the Amendment filed March 6, 2009 finds support in the specification at, for example, page 4, lines 18-21 of the specification as the above-noted passages describing aspects of claims 1 and 2.

The claims are believed to be supported by an adequate written description. The above is believed to be completely responsive to the Examiner's request for a showing of support for the claimed invention in the present specification.

An English translation of the specification is being prepared and the applicants plan to file a supplement to the present Response pointing to aspects of support for the

LAFONT et al.
Appl. No. 10/561,238
Atty. Ref.: 1721-108
Amendment
October 21, 2009

claims in the priority application. The Examiner is requested to contact the undersigned, preferably by telephone, in the event the Examiner reaches the application for action prior to the submission of the supplement.

Withdrawal of the Section 112, first paragraph "written description", rejection is requested.

The claims are submitted to be in condition for allowance and a Notice to that effect is requested. The Examiner is requested to contact the undersigned, preferably by telephone, in the event anything further is required.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: /B. J. Sadoff/
B. J. Sadoff
Reg. No. 36,663

BJS:
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100